StockData

Retractable Technologies vs Sonoma Pharmaceuticals

RVP and SNOA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RVP and SNOA compare

Retractable Technologies is the larger company, worth 4.2 times as much as Sonoma Pharmaceuticals ($16.9M against $4.0M).

Sonoma Pharmaceuticals grew revenue faster over the last twelve months (47.0% versus −11.2% for Retractable Technologies).

Retractable Technologies keeps more of each dollar of sales as profit, with a net margin of −9.9% compared with −10.3% at Sonoma Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRVPSNOA
Size and price
Market cap$16.9M$4.0M
Share price$0.565$0.834
Change, 1 year−27.4%−75.7%
Change, 5 years−93.5%−99.2%
Beta (5Y)0.392.15
Employees201250
StockData Score
Total score1111
Valuation score33
Growth score13 (better)
Performance score3 (better)2
Health score4 (better)3
Dividend score00
Valuation
P/S0.5×0.2× (better)
P/B0.2× (better)0.6×
FCF yield–−66.5%
Fair value$3.11$4.70
Margin of safety81.8%82.3% (better)
Growth
Revenue growth (TTM)−11.2%47.0% (better)
Revenue growth, 5Y average−14.1%0.95% (better)
Profitability
Gross margin−1.4%38.9% (better)
Operating margin−66.9%−6.4% (better)
Net margin−9.9% (better)−10.3%
FCF margin–−12.1%
Return on equity−4.5% (better)−42.5%
Return on invested capital−24.8% (better)−112%
Financial health
Debt / equity0.000.02 (better)
Interest coverage−278.8×–
Current ratio4.93 (better)2.99
Altman Z-score0.43 (better)−13.69
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield–−99.2%
Shareholder yield0.00% (better)−99.2%
Ownership
Held by institutions8.8%2.3%
Held by insiders55.7%11.1%
Insider net buying, 12 months$0–
Short interest, % of float0.17%1.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.